Regeneron Reports Two-Year (PULSAR) Trial Results of Aflibercept for Wet Age-Related Macular Degeneration
Shots:
- The 96wks. trial results evaluating aflibercept (8mg, 12 & 16wk. dosing regimens) vs 8wk. dosing regimen for Eylea in 1009 patients
- The trial met its 1EPs i.e., 88% were on a ≥12wk. dosing interval at the end of 2yrs., 78% maintained ≥12wk. dosing intervals throughout 2yr. study over 83% in 1yr. of study (48wks.), 71% met extension criteria for even longer dosing intervals incl. 47% for ≥20wk. intervals & 28% for 24wk. intervals, 70% maintained ≥16wk. dosing intervals throughout 2yr. study period; 78% & 53% were eligible for ≥16 & ≥20-dosing wk. intervals
- The safety continued to be similar to Eylea through 2yrs. & remained consistent with the known safety profile of Eylea from prior trials, vision gains were sustained, the rate of intraocular inflammation (1.3% vs 2.1%), arterial thromboembolic TEAEs (1.8% vs 3.3%)
Ref: Globenewswire | Image: Regeneron
Related News:- Regeneron Presented Two-Year Results from (PHOTON) Trial of Aflibercept for Diabetic Macular Edema at ASRS 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
